

28 February 2017

## Omni Innovation Update

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

### Media Coverage & New Website launched

On Saturday 28 January Channel 9 news ran a segment on the benefits of Faulding® GlucoControl™. The segment was broadcast nationally and is also available on Omni Innovation's website.

Omni Innovation launched a new website in early February, the updated site reflects the company focus on scientifically validated medical nutrition and has been well received by health care professionals, consumers and potential distribution partners.

### Marketing Programs

To reach a broader audience in a more cost effective way, Omni Innovation held its first educational webinar in mid-February about Faulding® GlucoControl™ aimed at diabetes educators and dieticians. The event was hosted by prominent cardiologist Dr Ross Walker and included a presentation from well-known dietician Dr Alan Barclay. It was well received by participants and more webinars are planned in the coming months.

A product sampling program targeting health care professionals to confirm the clinical benefits of the product in their professional practices is continuing with strong demand for samples.

### Second Tranche Investment into Omni Innovation

EVE has restructured the payment terms for the second tranche investment in Omni Innovation. The balance of \$625,000 has now been extended to 31 March 2017. Once this final payment has been made EVE will hold an approximate 40% interest in Omni Innovation.

### About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit [www.eveinvestments.com.au](http://www.eveinvestments.com.au) and follow us on Twitter @EVEInvestments

### About Omni Innovation

Omni Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In 2016, Faulding® GlucoControl™ was launched by the Company as its maiden product for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit [www.omniinnovation.com.au](http://www.omniinnovation.com.au)